Project Grant R37CA307076
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $396K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $223,176 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Duke University on September 10, 2025, with a completion date of April 30, 2028. This F32 postdoctoral fellowship award supports research investigating the role of SMARCAL1 (an annealing helicase) depletion in enhancing immunogenicity within Alternative Lengthening of Telomeres (ALT)-positive high-grade gliomas. The research addresses a...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $1.88 million Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded on September 23, 2025, with a completion date of August 31, 2029. The grant funds fundamental research to integrate genome-wide association study (GWAS) data with single-cell omics technologies to identify cellular effectors of glioblastoma predisposition. This research initiative...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $135,993 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective December 1, 2025, with completion anticipated by May 31, 2027. The award funds investigative research examining the role of the Abelson (ABL) kinase-regulated hypoxia inducible factor-1 alpha (HIF-1A) and transcriptional co-activator with PDZ-binding motif (TAZ) signaling...
- Federal Grant Award Summary Duke University received a $2.89 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion scheduled for July 31, 2029. This research project, titled "Understanding and Targeting Epigenetic Regulation of Immune Evasion in Prostate Cancer," will investigate how epigenetic mechanisms—specifically through the TNRC18 protein—regulate immune evasion in...
- Federal Grant Award Summary Duke University received a $497,972 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026 through March 31, 2031. The award supports research targeting enhancer of zeste homolog 2 (EZH2) as a therapeutic approach for advanced prostate cancer, particularly castration-resistant prostate cancer (CRPC). The research project focuses on developing and evaluating small-molecule EZH2...
- Federal Project Grant Award Summary Duke University received a $668,691 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on March 11, 2026, with a completion date of February 28, 2031. The award funds a hierarchical 2x2 factorial randomized controlled trial (RCT) testing two evidence-based interventions designed to improve treatment outcomes and quality of life for older women (age 65+) with hormone receptor-positive breast cancer...
- Federal Grant Award Summary Duke University received a $411,152 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 5, 2025, with a completion date of August 31, 2027. This research initiative addresses the identification and validation of noncovalent protein interactions associated with mutant KRAS (MKRAS) inhibitors, building upon recent advances in KRAS G12C-targeted therapeutics that have achieved FDA...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant totaling $624,194 under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026 through March 31, 2031. This five-year award supports fundamental research investigating how the integrated stress response (ISR) regulates CD8+ tumor-infiltrating lymphocyte (TIL) function and immunometabolism within the tumor microenvironment (TME). The research...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...